Baxter International (BAX) EBITDA (2009 - 2026)

Baxter International (BAX) has 18 years of EBITDA data on file, last reported at $66.0 million in Q1 2026.

• Quarterly EBITDA fell 65.98% year-over-year to $66.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $514.0 million (down 51.23% YoY) and the FY2025 annual result came in at -$308.0 million, down 2300.0% from the prior year.
• EBITDA rose to $66.0 million in Q1 2026 per BAX's latest filing, from -$33.0 million in the prior quarter.
• Across five years, EBITDA topped out at $2.6 billion in Q3 2023 and bottomed at -$2.9 billion in Q3 2022.
• The 5-year median for EBITDA is $146.0 million (2022), against an average of $102.9 million.
• The widest annual swing landed in 2022, when EBITDA tumbled 1456.52%; it then jumped 307.05% in 2023.
• Tracing BAX's EBITDA over 5 years: stood at -$312.0 million in 2022, then jumped by 307.05% to $646.0 million in 2023, then soared by 48.45% to $959.0 million in 2024, then slumped by 103.44% to -$33.0 million in 2025, then jumped by 300.0% to $66.0 million in 2026.
• Per Business Quant, the three latest BAX EBITDA figures stand at $66.0 million (Q1 2026), -$33.0 million (Q3 2025), and $287.0 million (Q2 2025).

Peer Comparison